Our story began with a team of scientists and visionaries looking to tackle one of healthcare’s greatest unmet needs: inflammatory diseases. When we recognized the potential for SERPIN proteins to mitigate these conditions, we committed to developing a first-in-class therapeutic to restore immune balance to harmful inflammatory environments.

Our therapeutic, now known as SP16, is currently undergoing pre-clinical and clinical trials for a broad span of orphan, chronic, and acute indications. We are currently collaborating with leaders across diverse fields of research to deliver our technology to the patients who need it most.